Document resource
Introduction In the UNITE trial ( NCT04041284), fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb), significantly improved migraine and depressive symptoms versus placebo in participants with migraine and major depressive disorder (MDD). This analysis estimated the potential economic impact of the UNITE results from a UK societal perspective.Methods An Excel-based cost-consequence model, with a 1-year time-horizon, was developed to estimate cost differences for people with migraine and MDD when only symptoms of migraine are treated with CGRP pathway mAbs (base case scenario) versus when symptoms of both migraine and MDD are treated with fremanezumab (alternate scenario). The model included people with migraine and MDD (≥18 years) eligible for CGRP pathway mAbs, current market shares (fremanezumab: 48%; other CGRP pathway mAbs: 52%) and drug/administration costs from MIMS UK and the National Schedule of National Health Service costs, 2024. Costs associated with healthcare resource utilisation and work productivity and impairment were estimated based on data from the 2022 EU and UK National Health and Wellness Survey.Results Total annual cost savings of £11,552.30 per person were estimated based on the existing market share of fremanezumab.Conclusion In people with migraine and MDD, fremanezumab treatment may result in substantial total cost savings.mark.fredericks@tevauk.com